2.00
Precedente Chiudi:
$1.99
Aprire:
$2
Volume 24 ore:
39,725
Relative Volume:
0.21
Capitalizzazione di mercato:
$99.69M
Reddito:
-
Utile/perdita netta:
$-6.48M
Rapporto P/E:
-14.60
EPS:
-0.137
Flusso di cassa netto:
$-5.30M
1 W Prestazione:
-2.91%
1M Prestazione:
-10.31%
6M Prestazione:
-28.32%
1 anno Prestazione:
+0.00%
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Nome
Polaryx Therapeutics Inc
Settore
Industria
Telefono
201-940-7236
Indirizzo
140 EAST RIDGEWOOD AVENUE, PARAMUS
Compare PLYX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
PLYX
Polaryx Therapeutics Inc
|
2.00 | 106.67M | 0 | -6.48M | -5.30M | -0.137 |
|
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-27 | Iniziato | Maxim Group | Buy |
Polaryx Therapeutics Inc Borsa (PLYX) Ultime notizie
We Think Polaryx Therapeutics (NASDAQ:PLYX) Can Afford To Drive Business Growth - Sahm
This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Sahm
Polaryx Therapeutics (PLYX) cuts losses as cash rises to $11.5M - Stock Titan
Polaryx Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Raymond James Initiates Polaryx Therapeutics(PLYX.US) With Buy Rating, Announces Target Price $6 - Moomoo
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Polaryx Therapeutics (NASDAQ:PLYX) Coverage Initiated at Raymond James Financial - MarketBeat
PLYX Initiated Coverage by Raymond James -- Strong Buy Rating An - GuruFocus
Raymond James Initiates Polaryx Therapeutics at Strong Buy - marketscreener.com
Raymond James initiates Polaryx Therapeutics stock with strong buy By Investing.com - Investing.com South Africa
Raymond James initiates Polaryx Therapeutics stock with strong buy - Investing.com Nigeria
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference - 富途牛牛
Polaryx Therapeutics Ord Shs (PLYX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polaryx Therapeutics, Inc. Common Stock (NASDAQ: PLYX) Stock Price, News & Analysis - Kalkine
PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits
Polaryx Therapeutics (PLYX) sets 2026 virtual meeting, director votes and auditor - Stock Titan
PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Se - GuruFocus
PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Set to Buy - GuruFocus
Lucid Capital initiates Polaryx stock with buy rating on rare disease therapy potential - Investing.com Canada
PLYX|Polaryx Therapeutics Ord Shs|Price:2.096|Chg%:-0.024 - TradingKey
Polaryx Therapeutics, Inc. Revenue Breakdown – NASDAQ:PLYX - TradingView
Polaryx Therapeutics Ord Shs (PLYX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PLYX|Polaryx Therapeutics Ord Shs|Price:2.090|Chg%:-0.010 - TradingKey
Polaryx Therapeutics, Inc. Revenue Breakdown – BOATS:PLYX - TradingView
Polaryx Therapeutics Announces Chief Medical Officer Resignation - The Globe and Mail
Polaryx Therapeutics (PLYX) Slips 3.45%: Support Level Tested at $2.13Iron Condor Alert - vinanet.vn
Polaryx Therapeutics, Inc. Files Form 8-K as Emerging Growth Company on NASDAQ (PLYX) – July 2026 - Minichart
Polaryx Therapeutics' Lisa Bollinger resigns as Chief Medical Officer - TradingView
Polaryx Therapeutics, Inc. Announces Resignation of Lisa Bollinger from Chief Medical Officer, Effective July 19, 2026 - marketscreener.com
Polaryx Sets 2026 Virtual Annual Shareholder Meeting - TipRanks
Polaryx Therapeutics (PLYX) schedules 2026 virtual annual meeting and proposal deadline - Stock Titan
Polaryx Therapeutics (PLYX) Edges Higher Amidst Narrow Trading RangeDouble Top - vinanet.vn
What is HC Wainwright's Forecast for PLYX Q2 Earnings? - MarketBeat
Polaryx Therapeutics (NASDAQ:PLYX) Downgraded by Wall Street Zen to "Sell" - MarketBeat
PLYX News Today | Why did Polaryx Therapeutics stock drop today? - MarketBeat
H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating - Investing.com
PLYX Initiates Coverage On Polaryx Therapeutics -- Price Target Set at $7.00 - GuruFocus
Polaryx Therapeutics Initiated at Buy by HC Wainwright & Co. - Moomoo
Polaryx Therapeutics (PLYX) Stock Analysis Report | Financials & Insights - Benzinga España
Operating cash flow per share of Polaryx Therapeutics, Inc. – FWB:1V8 - TradingView
Free cash flow per share of Polaryx Therapeutics, Inc. – FWB:1V8 - TradingView
Polaryx Therapeutics (PLYX) Surges 7.7%: Momentum Builds Above Key SupportInstitutional Sentiment - DonanımHaber
Polaryx Therapeutics (PLYX) Holds Steady Near Support as Technical Indicators Signal ConsolidationSector Sentiment - dars.gov.et
Enterprise value to EBIT forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Enterprise value to revenue forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Price to sales forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Price to earnings forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Polaryx Therapeutics, Inc. Actuals & Estimates (NASDAQ:PLYX) - TradingView
PLYX Forecast — Price Target — Prediction for 2027 - TradingView
Polaryx Therapeutics Ord Shs (PLYX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polaryx Therapeutics Inc Azioni (PLYX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Polaryx Therapeutics Inc Azioni (PLYX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Landis G. Michael | Chief Financial Officer |
Feb 18 '26 |
Buy |
2.79 |
2,867 |
7,991 |
228,225 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):